ID   NK-92
AC   CVCL_2142
SY   NK92; Natural Killer-92; NK-92.05; Neukoplast; aNK
DR   BTO; BTO_0003287
DR   CLO; CLO_0008177
DR   EFO; EFO_0022517
DR   AddexBio; C0003026/NA
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-2407
DR   BCRC; 60414
DR   BioSample; SAMN03471836
DR   CCRID; 4201HUM-CCTCC00052
DR   CCTCC; GDC0052
DR   Cell_Model_Passport; SIDM01143
DR   Cosmic; 1534874
DR   Cosmic; 1542071
DR   Cosmic; 2025326
DR   Cosmic; 2390215
DR   Cosmic; 2785204
DR   DSMZ; ACC-488
DR   DSMZCellDive; ACC-488
DR   GEO; GSM472001
DR   IPD-IMGT/HLA; 13674
DR   Lonza; 1093
DR   Wikidata; Q17149636
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=8152260;
RX   PubMed=9118301;
RX   PubMed=9573023;
RX   PubMed=10365666;
RX   PubMed=10803505;
RX   PubMed=11454312;
RX   PubMed=12850795;
RX   PubMed=16827800;
RX   PubMed=18424763;
RX   PubMed=19194464;
RX   PubMed=20454443;
RX   PubMed=21052088;
RX   PubMed=21570725;
RX   PubMed=25586472;
RX   PubMed=26559813;
RX   PubMed=30054012;
RX   PubMed=31126350;
RX   PubMed=31160637;
RX   PubMed=34349345;
RX   PubMed=36610812;
WW   Info; -; -; https://web.archive.org/web/20211125114549/http://www2.kumc.edu/soalab/LabLinks/cell%20lines/nk92.htm
WW   Info; ATCC; -; https://www.atcc.org/en/support/technical-support/faqs/growth-and-morphology-of-nk-92-cells
WW   Info; ClinicalTrials.gov; NCT00900809; https://clinicaltrials.gov/study/NCT00900809
WW   Info; ClinicalTrials.gov; NCT00990717; https://clinicaltrials.gov/study/NCT00990717
WW   Info; ClinicalTrials.gov; NCT02465957; https://clinicaltrials.gov/study/NCT02465957
WW   Info; Wikipedia; -; https://en.wikipedia.org/wiki/NK-92
WW   Provider; Brink Biologics; -; https://brinkbiologics.com/platform/
CC   Group: Patented cell line.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6670.
CC   Population: Caucasian.
CC   Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections.
CC   Characteristics: IL2 dependent.
CC   Characteristics: Does not express FCGR3A/CD16.
CC   Doubling time: 35.6 +- 6.1 hours (PubMed=31126350); ~40-50 hours (DSMZ=ACC-488).
CC   HLA typing: A*03:01:01,11:01:01; B*07:02:01,44:03:01; C*07:02:01,16:01:01; DPA1*01:03:01,01:03:01; DQB1*06:02:01,06:02:01 (DSMZCellDive=ACC-488).
CC   Sequence variation: Mutation; HGNC; HGNC:882; ATR; Unexplicit; Ex29-34del; Zygosity=Heterozygous (PubMed=16827800).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing.
CC   Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.
CC   Discontinued: AddexBio; C0003026; true.
CC   Discontinued: BCRC; 60414; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Natural killer cell; CL=CL_0000623.
ST   Source(s): ATCC=CRL-2407; DSMZ=ACC-488; Technion Genomics Center
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D10S1248: 14,15
ST   D12S391: 19,22
ST   D13S317: 9,12
ST   D16S539: 11,12
ST   D18S51: 12,17
ST   D19S433: 14,15
ST   D1S1656: 12,14
ST   D21S11: 31.2,32
ST   D22S1045: 12,17
ST   D2S1338: 19,20
ST   D2S441: 19,20
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   D8S1179: 12,15
ST   DYS391: 12
ST   FGA: 20,22
ST   Penta D: 10,12
ST   Penta E: 12
ST   TH01: 6,9.3
ST   TPOX: 8
ST   vWA: 16,18 (DSMZ=ACC-488; Technion Genomics Center)
ST   vWA: 18 (ATCC=CRL-2407)
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 36
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=8152260;
RA   Gong J.-H., Maki G., Klingemann H.-G.;
RT   "Characterization of a human cell line (NK-92) with phenotypical and
RT   functional characteristics of activated natural killer cells.";
RL   Leukemia 8:652-658(1994).
//
RX   PubMed=9118301;
RA   Klingemann H.-G., Wong E., Maki G.;
RT   "A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from
RT   blood.";
RL   Biol. Blood Marrow Transplant. 2:68-75(1996).
//
RX   PubMed=9573023; DOI=10.1182/blood.V91.10.3850;
RA   Nagashima S., Mailliard R., Kashii Y., Reichert T.E., Herberman R.B.,
RA   Robbins P., Whiteside T.L.;
RT   "Stable transduction of the interleukin-2 gene into human natural
RT   killer cell lines and their phenotypic and functional characterization
RT   in vitro and in vivo.";
RL   Blood 91:3850-3861(1998).
//
RX   PubMed=10365666; DOI=10.1089/10430349950018030;
RA   Tam Y.K., Maki G., Miyagawa B., Hennemann B., Tonn T.,
RA   Klingemann H.-G.;
RT   "Characterization of genetically altered, interleukin 2-independent
RT   natural killer cell lines suitable for adoptive cellular
RT   immunotherapy.";
RL   Hum. Gene Ther. 10:1359-1373(1999).
//
RX   PubMed=10803505; DOI=10.1038/sj.leu.2401778;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   natural killer cell leukemia-lymphoma.";
RL   Leukemia 14:777-782(2000).
//
RX   PubMed=11454312; DOI=10.1089/152581601750288975;
RA   Maki G., Klingemann H.-G., Martinson J.A., Tam Y.K.;
RT   "Factors regulating the cytotoxic activity of the human natural killer
RT   cell line, NK-92.";
RL   J. Hematother. Stem Cell Res. 10:369-383(2001).
//
RX   PubMed=12850795; DOI=10.1080/14653240310001523;
RA   Tam Y.K., Martinson J.A., Doligosa K., Klingemann H.-G.;
RT   "Ex vivo expansion of the highly cytotoxic human natural killer-92
RT   cell-line under current good manufacturing practice conditions for
RT   clinical adoptive cellular immunotherapy.";
RL   Cytotherapy 5:259-272(2003).
//
RX   PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x; PMCID=PMC11159954;
RA   Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.;
RT   "Alterations in ATR in nasal NK/T-cell lymphoma and chronic active
RT   Epstein-Barr virus infection.";
RL   Cancer Sci. 97:605-610(2006).
//
RX   PubMed=18424763; DOI=10.4049/jimmunol.180.9.6392; PMCID=PMC2810560;
RA   Binyamin L., Alpaugh R.K., Hughes T.L., Lutz C.T., Campbell K.S.,
RA   Weiner L.M.;
RT   "Blocking NK cell inhibitory self-recognition promotes
RT   antibody-dependent cellular cytotoxicity in a model of anti-lymphoma
RT   therapy.";
RL   J. Immunol. 180:6392-6401(2008).
//
RX   PubMed=19194464; DOI=10.1038/leu.2009.3;
RA   Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H.-M.,
RA   Klinkebiel D.L., Christman J.K., Patel K.N., Cao K., Shen L., Dybkaer K.,
RA   Tsui I.F.L., Ali H.H., Shimizu N., Au W.Y., Lam W.L., Chan W.-C.;
RT   "Genomic analyses reveal global functional alterations that promote
RT   tumor growth and novel tumor suppressor genes in natural killer-cell
RT   malignancies.";
RL   Leukemia 23:1139-1151(2009).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
//
RX   PubMed=21052088; DOI=10.1038/leu.2010.255;
RA   Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.-Y., Srivastava G.,
RA   Greiner T.C., Kucuk C., Deffenbacher K.E., Vose J.M., Smith L., Au W.Y.,
RA   Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H.,
RA   Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.-C.;
RT   "Natural killer cell lymphoma shares strikingly similar molecular
RT   features with a group of non-hepatosplenic gammadelta T-cell lymphoma
RT   and is highly sensitive to a novel aurora kinase A inhibitor in
RT   vitro.";
RG   International Peripheral T-cell Lymphoma Project;
RL   Leukemia 25:348-358(2011).
//
RX   PubMed=21570725; DOI=10.1016/j.molimm.2011.04.010;
RA   Schnueriger A., Grau R., Sondermann P., Schreitmueller T., Marti S.,
RA   Zocher M.;
RT   "Development of a quantitative, cell-line based assay to measure ADCC
RT   activity mediated by therapeutic antibodies.";
RL   Mol. Immunol. 48:1512-1517(2011).
//
RX   PubMed=25586472; DOI=10.1038/ncomms7025; PMCID=PMC7743911;
RA   Kucuk C., Jiang B., Hu X.-Z., Zhang W.-Y., Chan J.K.C., Xiao W.-M.,
RA   Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A.,
RA   Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W.-W., Cornish A.,
RA   Gong Q., Yang Q.-P., Sun H., d'Amore F.A., Leppa S., Liu W.-P., Fu K.,
RA   de Leval L., McKeithan T.W., Chan W.-C.;
RT   "Activating mutations of STAT5B and STAT3 in lymphomas derived from
RT   gammadelta-T or NK cells.";
RL   Nat. Commun. 6:6025.1-6025.12(2015).
//
RX   PubMed=26559813; DOI=10.1007/s00262-015-1761-x; PMCID=PMC11029582;
RA   Suck G., Odendahl M., Nowakowska P., Seidl C., Wels W.S.,
RA   Klingemann H.-G., Tonn T.;
RT   "NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer
RT   cell-based cancer immunotherapy.";
RL   Cancer Immunol. Immunother. 65:485-492(2016).
//
RX   PubMed=30054012; DOI=10.1016/j.molimm.2018.07.015; PMCID=PMC6345623;
RA   Gunesch J.T., Angelo L.S., Mahapatra S., Deering R.P., Kowalko J.E.,
RA   Sleiman P., Tobias J.W., Monaco-Shawver L., Orange J.S., Mace E.M.;
RT   "Genome-wide analyses and functional profiling of human NK cell
RT   lines.";
RL   Mol. Immunol. 115:64-75(2019).
//
RX   PubMed=31126350; DOI=10.1186/s40425-019-0612-2; PMCID=PMC6534912;
RA   Yang H.G., Kang M.C., Kim T.Y., Hwang I., Jin H.T., Sung Y.C.,
RA   Eom K.-S., Kim S.W.;
RT   "Discovery of a novel natural killer cell line with distinct
RT   immunostimulatory and proliferative potential as an alternative
RT   platform for cancer immunotherapy.";
RL   J. Immunother. Cancer 7:138.1-138.17(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218.1-8218.14(2019).
//
RX   PubMed=34349345; DOI=10.1007/s10616-021-00476-1; PMCID=PMC8319282;
RA   Zhao H., Zhou Z.-L., Li G.-M., Liu G., Lin S.-Y., Chen W., Xiong S.;
RT   "An NK cell line (NK92-41BB) expressing high levels of granzyme is
RT   engineered to express the high affinity chimeric genes CD16/CAR.";
RL   Cytotechnology 73:539-553(2021).
//
RX   PubMed=36610812; DOI=10.1016/j.jcyt.2022.12.003;
RA   Klingemann H.-G.;
RT   "The NK-92 cell line -- 30 years later: its impact on natural killer cell
RT   research and treatment of cancer.";
RL   Cytotherapy 25:451-457(2023).
//